Article

Epithalon (Ala-Glu-Asp-Gly): the pineal tetrapeptide and its research record

Published 23 October 2026 · CognitivePepti Research Desk

Abstract double-helix strand in violet tones on a dark background

Prepared by: Research Desk. Sources are linked for verification.

Published 23 October 2026

At a glance

Type: synthetic linear tetrapeptide (4 amino acids) with the sequence Ala-Glu-Asp-Gly (AEDG), spelled Epitalon or Epithalon in the literature
Origin: developed at the St Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues, based on amino-acid analysis of the bovine pineal extract Epithalamin
Research stage: predominantly cell-culture and rodent studies from the originating Russian school, plus recent independent cell-line studies and narrative reviews
Regulatory status: not an FDA-approved drug. Listed as Epitalon on the agenda of FDA's 23–24 July 2026 Pharmacy Compounding Advisory Committee meeting and on FDA's page of bulk drug substances that may present significant safety risks.

Origin and sequence

Epithalon (also spelled Epitalon) is the four-residue peptide L-alanyl-L-glutamyl-L-aspartyl-glycine (Ala-Glu-Asp-Gly, or AEDG). As reviewed in a 2025 paper in the International Journal of Molecular Sciences (Araj et al., 2025, PubMed) and a follow-up October 2026 narrative review in the same journal (PubMed), the peptide was designed in St Petersburg as a defined synthetic counterpart to Epithalamin, a polypeptide extract prepared from bovine pineal glands.

Whereas Semax and Selank came out of the Moscow glyproline and tuftsin programmes (covered in our Semax research overview and Selank research overview), Epithalon belongs to a separate Russian research tradition focused on very short di-, tri- and tetrapeptides, often termed "cytomedines" or "bioregulatory peptides" by their developers.

Because Ala-Glu-Asp-Gly contains two acidic side chains (glutamate and aspartate) and no bulky hydrophobic or aromatic residues, it is highly polar and water-soluble, with a molecular mass of roughly 390.35 g/mol.

Mechanisms studied in cell and animal work

Most experimental papers on Epithalon fall into three areas: telomere length measurements in cultured cells, gene-expression and neuronal-differentiation assays, and rodent lifespan or circadian-rhythm models.

Telomere length and telomerase in cell lines

Early reports from the St Petersburg group claimed that adding Epithalon to cultured human fetal fibroblasts induced telomerase activity and elongated telomeres across serial passages. More recently, a September 2025 study in Biogerontology (PubMed; see also the November 2025 correction notice at PubMed) examined telomere length in human normal and cancer cell lines exposed to Epithalon in vitro, reporting changes in telomerase subunit expression in normal cells alongside alternative lengthening of telomeres (ALT) markers in tumour lines.

Cell-culture telomere measurements do not show how a tetrapeptide behaves in an intact organism, and activating telomere-maintenance pathways in transformed cell lines raises separate biological questions that in-vitro assays alone cannot resolve.

Gene expression, epigenetic models and neuronal differentiation

The St Petersburg group has proposed that very short peptides such as AEDG can enter cell nuclei and interact directly with histone proteins or specific DNA promoter motifs. A September 2025 review in Current Issues in Molecular Biology (PubMed) summarised cell-culture experiments reporting changes in neurogenic differentiation markers (such as Nestin, GAP43 and beta-tubulin III) and senescence-associated markers in cultured stem and progenitor cells.

A separate August 2025 in-vitro study in Stem Cell Reviews and Reports (PubMed) tested Epithalon in a high-glucose human retinal pigment epithelial cell scratch assay, measuring reactive oxygen species and wound-closure speed in culture dishes.

Rodent circadian and pineal models

In rodents and aged monkeys, earlier papers from the developing institute measured nocturnal plasma melatonin peaks and antioxidant enzyme activity after repeated administration of Epithalamin or synthetic Epithalon (Araj et al., 2025, PubMed).

The published research landscape and its limits

A central theme of the October 2026 narrative review of Epitalon and Epithalamin (PubMed) is the gap between the volume of preclinical claims and the rigour of the clinical record:

Concentration of authorship. For more than two decades, the vast majority of publications on AEDG came from a single network of laboratories in St Petersburg. Independent replication outside Eastern Europe has begun only recently and remains largely confined to in-vitro cell lines.
Conflation of Epithalamin and Epithalon. Several human studies cited in secondary articles actually tested Epithalamin—the unfractionated bovine pineal tissue extract—rather than the pure synthetic tetrapeptide Ala-Glu-Asp-Gly. Results from a multi-component tissue extract cannot be attributed to a single four-amino-acid sequence.
Absence of modern controlled human trials. No large, randomised, double-blind, placebo-controlled human trials of synthetic Epithalon indexed in PubMed establish clinical outcomes or long-term human safety.

For how this pattern compares with Semax, Selank and DSIP, see our cognition peptide research guide and our DSIP research overview.

Regulatory status

FDA approval. Epithalon (Epitalon) is not an FDA-approved drug for any indication.
FDA safety-risk page. FDA's page on bulk drug substances that may present significant safety risks lists Epitalon among substances identified under its interim compounding policy as presenting significant safety risks, noting the lack of adequate human safety data and characterisation.
July 2026 Pharmacy Compounding Advisory Committee. FDA's meeting page for the 23–24 July 2026 Pharmacy Compounding Advisory Committee listed Epitalon for discussion on 24 July 2026 alongside Emideltide (DSIP) and Semax as bulk drug substances evaluated under section 503A. A July–August 2026 analysis in the International Journal of Pharmaceutical Compounding (PubMed) reviewed the committee's evaluations of synthetic peptides and the safety standards applied to nominated bulk substances.

Open research questions

Cellular uptake and binding target. Direct biophysical proof of how a hydrophilic tetrapeptide crosses cell and nuclear membranes and whether it binds a specific protein or DNA sequence at physiological concentrations remains incomplete.
Extract versus tetrapeptide. Disentangling historical data generated with bovine pineal extract (Epithalamin) from experiments using pure synthetic AEDG.
Independent in-vivo replication. Whether the rodent lifespan and melatonin findings reported by the originating institute hold up in preregistered, independently run animal studies.

Key terms

Tetrapeptide. A peptide chain composed of four amino acids linked by peptide bonds.
Epithalamin. A polypeptide extract prepared from bovine pineal tissue, distinct from the synthetic tetrapeptide Epithalon (Ala-Glu-Asp-Gly).
Telomerase and ALT. Two cellular mechanisms that maintain telomere length at chromosome ends: the ribonucleoprotein enzyme telomerase, and recombination-based alternative lengthening of telomeres (ALT).

Supplier

Purita is a store that sells peptides for laboratory research use only, and its product pages label items for research use only and not for human or animal administration.

Visit the Purita website

Affiliate disclosure: this is a paid link. CognitivePepti earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the affiliate disclosure.